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Abstract: We construct a dataset that contains the complete set of patent cases filed at the 
courts in England and Wales during the period 2000-2008. The data cover all types of patent-
related cases brought before the Patents County Court, the Patents Court at the High Court, 
the Court of Appeal, as well as the House of Lords/Supreme Court. We combine the detailed 
information on court cases with information on the patents in dispute as well as firm-level data 
for the litigating parties. We employ the dataset to analyse characteristics of the (a) court cases, 
(b) litigating parties, as well as (c) the contested patents. We also provide detailed discussion of 
the cases that were heard by the House of Lords/Supreme Court as well as of the costs 
involved in patent litigation before the courts in England and Wales.  
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“IP litigation may be expensive but, if you look after it properly, it will ultimately 
look after you.” 
    
                                                                                       Jeremy Philips (2006) 
 
“[...] [T]here are unlikely to be winners when an issue reaches court. Use of a court 
to reach a decision is probably the most expensive way to reach a decision and one 
that the system should be designed to avoid.” 
 
                                                                                          Greenhalgh et al. (2010) 
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1. INTRODUCTION 
 
Patent litigation has risen to dubious worldwide fame ever since the ‘global patent 
wars’ broke out between the giants in the information and communication 
technology (ICT) industry.1 Moreover, while the patent wars have clearly led to a 
surge in patent court cases in all major markets,2 it is also clear that the publicity 
surrounding these court battles has shed light on the fact that in some industries 
patent litigation is rapidly becoming a primary mechanism for moving issues of 
competition from the product market into the court room. Concern about the 
disruptive potential of patent litigation has also increased in recent years due to the 
increased participation in litigation of so-called ‘patent trolls’, sometimes referred 
to as ‘patent assertion entities’ (PAEs) or ‘non-producing entities’ (NPEs) (Bessen 
et al., 2011). The prominence of these cases in the eyes of the media has 
reinforced a broader public debate concerning innovation within the patent system 
and the role of litigation. 
The functioning of the patent system fundamentally depends upon the ability 
of patentees to enforce their rights, if necessary with the help of courts. In 
particular, the role of patents in the dissemination of information by requiring the 
disclosure of detailed technical information relies on enforceable patent rights in 
order to provide firms with the incentive to make this information publicly 
accessible. Patents are also designed to encourage transactions via licensing and 
assignment; there is no doubt that enforceability is crucial for enabling these 
transactions. In this regard, Bessen and Meurer (2005) suggest that the value of 
patenting springs entirely from the threat of litigation, rather than the taking of 
actual legal proceedings. Empirical evidence by Lanjouw and Schankerman (2004) 
supports this hypothesis for the US. At the same time, the recent global patent 
wars within the ICT industry, including the increased involvement of PAEs, have 
also shown the potential for patent litigation to become a disruptive force with 
respect to product market competition and innovation. 
While the state confers the legal right to exclude third parties from the use of 
intellectual property (IP), the state does not directly enforce this right itself. 
Instead, right-holders are required to enforce their rights through the institutions 
established by the state for this purpose. This implies that right-holders are tasked 
                                                     
1 There has been extensive media coverage of the ‘global patent wars’. See for example The Wall Street 
Journal (Crovitz, Gordon ‘Google, Motorola and the Patent Wars,’ August 22, 2011), the Financial 
Times (Oberlander, Marissa, Martin Stabe and Steve Bernard, ‘The Smartphone Patent Wars,’ October 
17, 2011), the Washington Post (Basulto, Dominic, ‘Patent Wars 2012: Here’s What to Expect,’ January 
4, 2012). 
2 The Boston Globe (Bray, Hiawatha, ‘High Stakes Fueling Patent Wars,’ December 26, 2011) reported 
that Apple, Samsung, Google, and Microsoft were engaged in over 100 patent suits in at least 10 
different countries at the end of 2011. The figure is likely to have substantially increased since then. 
The Guardian (Halliday, Josh and Charles Arthur, ‘Microsoft Sues Motorola over Android – and all the 
Other Mobile Lawsuits, Visually,’ October 5, 2010) published a table showing the various criss-cross 
lawsuits in the ICT sector; accessible at 
http://www.guardian.co.uk/technology/2010/oct/04/microsoft-motorola-android-patent-lawsuit. 
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with monitoring every potential infringement of their rights. Once a potential 
infringement has been identified, right-holders must decide whether to seek 
remediation. Consequently, full legal action/proceedings will not be taken with 
respect to every infringement of an existing IP right. A decision to take legal 
action inevitably depends on an assessment of the benefits and costs associated 
with monitoring infringement and taking legal action. Factors determining whether 
the owner of a potentially infringed patent takes legal action include (Weatherall et 
al., 2009): (1) the amount of sales foregone due to the existence of IP 
infringement; (2) the degree of competitive disadvantage which accrues when a 
comparison is made with those enterprises that are able to free-ride on the R&D 
and marketing expenses of the right-holding firm; (3) the potential for loss of 
goodwill and prestige with regard to a brand, if counterfeits are freely available; 
and (4) the expense of monitoring the market and instituting legal proceedings. 
Obviously, all of these factors are difficult to measure, not least because of the 
absence of the counterfactual. For example, the issue of what a product’s market 
share might have been in the absence of infringement is a difficult factor to 
measure accurately. The overall costs of undertaking litigation are due to a host of 
factors including: (a) the effort undertaken in order to observe and assess potential 
incidences of infringement, (b) the ability to identify the infringer(s), (c) an 
assessment of whether the IP right is likely to stand up in court e.g. the validity of 
a patent, and (d) the (substantial) direct and indirect financial costs of the litigation 
itself. The complex interplay between these factors may explain why existing 
research as well as anecdotal evidence suggests that only a tiny proportion of 
patent disputes eventually end up in court (Greenhalgh et al., 2010).  
Furthermore, infringement of patent rights often occurs when firms are 
unaware of existing rights which they are in fact infringing.3 Alternatively, 
infringement may be undertaken wilfully, either for strategic purposes or because 
firms learn about the infringed patent only when the sunk cost for a research 
project has already been paid (Bessen and Meurer, 2006). In fact, Lemley (2008) 
suggests that firms in the IT and biotech industry in the US ignore existing patent 
rights on purpose in order to avoid wilful infringement. Cockburn and Henderson 
(2003) provide survey evidence collected from company IP managers. This 
research shows that only a third of respondents conduct a prior art search before 
starting new R&D or product development.  
From the point of view of right-holders, owners of infringed rights may 
possess one or more of a variety of motives for taking litigation. Most importantly, 
a right-holder can seek to use litigation to exclude its competitors from using a 
patented technology. Alternatively, a right-holder can force its competitors to 
acquire a licence for the patent right. A law suit also provides the possibility for 
the negotiation and collection of settlement payments, which could be used to 
                                                     
3 This is illustrated by the famous settlement in the case New Technologies Products (NTP) vs Research In 
Motion (RIM) in March 2006 where RIM agreed to pay NTP US$ 612.5 million for the infringement of 
five patents that it was unaware of when developing the software protected by the patents enforced by 
NTP.  
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weaken a competing firm or could even be used to push smaller firms out of the 
market. Litigation may also be used for more strategic motives, such as the case of 
a dominant incumbent firm which threatens to sue smaller, actual or potential 
competitors to prevent market entry. 
The existing empirical literature on patent litigation overwhelmingly uses US 
court data, supposedly because US data are relatively easily accessible. Much less is 
known about patent litigation in other jurisdictions. Given the in part substantial 
differences in the enforcement systems across countries, empirical findings for the 
US may not carry over directly to other jurisdictions. The aim of this article is to 
provide empirical evidence on the enforcement of patents within the UK, and the 
legal system of the Patents Court (PHC)4 of England and Wales in particular as it 
is the venue where the majority of patent litigation in the UK takes place.  
Courts in the UK are widely regarded as ‘thorough’, a description which has 
given the UK courts an ‘anti-patent’ reputation. This reputation has led potential 
claimants in infringement cases to seek to avoid litigation in the UK, whereas 
potential defendants and other parties regard the UK as a propitious jurisdiction 
for challenging the validity of patents and/or claiming non-infringement (Moss et 
al., 2010). Legal procedures in the UK are also reputed for their costs (Weatherall 
et al., 2009; Burdon, 2010; see also Section 3.3), but the UK courts are also 
considered to be relatively fast-working. However, so far there is little factual 
empirical evidence supporting these claims. This article provides factual empirical 
evidence, based on a study of all patent cases filed at the Patents Court (PHC) 
from 2000 to 2008 as well as the Patents County Court (PCC) for 2007 and 2008. 
Our analysis shows that patent litigation is extremely rare: we only observe 
255 patent cases at the PHC over the nine-year period studied. While the media 
coverage on the patent wars and PAEs may create the impression that patent 
litigation concerns only the ICT giants and patent trolls, our data show that patent 
cases in pharma/chemicals are far more frequent and cases involving PAEs 
accounted for less than 6% of all cases.5 The concentration of litigation at the 
PHC in pharma/chemicals is also reflected in the share of pharmaceutical and 
chemical companies in the population of companies involved in litigation before 
the PHC. Our data show that a third of all litigating companies are in the 
pharmaceutical and chemical industry. Our data also reveal the number of foreign 
litigants by far exceeds domestic parties. Most patents are aged between six and 
ten years at the moment they are litigated. A comparison of the set of litigated 
patents with a matched sample of control patents that have not been litigated 
shows that litigated patents are considerably more valuable as measured by 
standard patent-value metrics. They are also broader and contain more references 
to prior art including the non-patent literature. About 43% of all court cases are 
filed alleging the infringement of a patent whereas around 31% of cases seek the 
                                                     
4 The Patents Court is referred to within this article as the Patent High Court (PHC) in order to 
distinguish it from the Patents County Court (PCC). 
5 We analyse litigation involving PAEs in a companion paper (Helmers and McDonagh, 2012). 
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revocation of a patent. Only about half of all cases proceed to final judgment. 
Among those cases that ended with a judgment, we find that the by far the most 
likely outcome is the revocation of a patent – regardless of whether the case was 
filed as an infringement or revocation action. This confirms the widely shared 
view based on anecdotal evidence that the PHC is likely to invalidate patents in 
court. We also have some evidence on the costs of litigation. Our data indicate 
that most cases involve total costs for both claimant(s) and defendant(s) at the 
order of £1 million to £6 million, which also confirms the view that patent 
litigation before courts in England and Wales is extremely costly. 
The remainder of the article is organised as follows. Section 2 briefly 
discusses the available empirical evidence for the UK. Section 3 provides a 
thorough description of the legal system for the enforcement of patents in the 
UK. Section 4 describes the data used in Section 5 for the analysis of patent 
litigation in the UK. Section 6 provides a brief summary and conclusion. 
 
 
 
2. EXISTING EMPIRICAL EVIDENCE ON PATENT 
LITIGATION IN THE UK 
 
Weatherall et al. (2009) provide a comprehensive literature review with a focus on 
the UK in which they note the general lack of evidence with respect to the UK 
regarding the initial analysis of IP infringement by firms and the subsequent 
actions taken by firms when they find that their patents are being infringed. This 
lack of evidence is also apparent with regard to information concerning the use of 
formal, as well as informal, enforcement procedures and with respect to firms’ 
motives for either settling cases out of court or for pursuing infringement cases up 
to a court judgment. 
To the best of our knowledge, the only previous empirical study on the 
subject of patent litigation in the UK is Moss et al. (2010). The authors examine 
the outcomes of 47 validity and infringement cases between January 2008 and 
August 2009 by the Patents County Court, the Patents Court, the Court of Appeal, 
and the House of Lords (for an explanation of the division of these courts see 
Section 3). 18 out of these 47 cases (38% success rate) were won by the patentee, 
i.e. the patent was considered to be infringed and/or valid. 
Greenhalgh et al. (2010) collect survey evidence on about 100 patenting and 
non-patenting firms (alive between 2002 and 2009) to investigate the IP litigation 
activity of micro firms and SMEs in the UK. According to their survey, 
approximately 40% of patent holding firms have been involved in some kind of IP 
dispute during the five years before the survey. In addition, firms that do not hold 
patents are much less likely to be subject to legal action due to alleged 
infringement (7% report a dispute). Greenhalgh et al. (2010) also note that firms 
were generally as likely to be involved in a dispute with another firm of the same 
or smaller size as they were with a larger company. Furthermore, with regard to 
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infringement micro firms and SMEs are more likely to be complainants, rather 
than defendants. The survey also offers some insight with regard to disputes that 
never made it to court - the “litigation iceberg that lurks under water”. Greenhalgh 
et al. (2010) find that the vast majority of firms first attempt to resolve a dispute 
through the exchange of letters between solicitors, which appears to resolve a 
substantial fraction of the disputes. According to their study, only about 13% of 
disputes end up in court. The study also offers some insights with regard to the 
obstacles to litigation. For example, firms stated that financial costs, in particular 
legal fees, were the principal obstacle to litigation. On top of the direct financial 
costs, firms expressed concerns regarding the time that managers and engineers 
who are involved in R&D would be forced to devote to litigation, effectively 
diverting scarce resources from more productive activities. Despite the high costs 
of litigation, only about 25% of firms have IP insurance as ex ante; it is considered 
too costly by firms and some firms also expressed concerns that insurers might 
press for early settlement if the chances for winning the case were perceived as not 
sufficiently large. 
 
 
  
3. LEGAL FRAMEWORK 
 
3.1 OVERVIEW 
 
There is no unified legal system for the UK. England and Wales, Scotland, and 
Northern Ireland have separate legal systems and courts.6 In England and Wales, 
there are two courts of relevance to this study, the Patents County Court (PCC), 
which deals with low-value claims, and the Patents Court (PHC), which is a 
specialist court of the Chancery Division of the High Court of Justice of England 
and Wales.7 As previously noted, in principle the PCC hears cases of lower value 
and complexity, such as disputes involving SMEs.8 
In practice, however, nearly all cases are heard by the PHC, which is the 
principal subject of our study (see Section 5). At both the PCC and the PHC, each 
case is tried by a single judge who possesses IP-specific expertise. In England and 
                                                     
6 While IP infringement can also be enforced through criminal law, we focus on the civil enforcement 
procedures because the criminal courts are rarely relevant in the context of patent litigation. 
7 The Queen’s Bench Division may hear cases related to patent licensing. The Technology and 
Construction Court may incidentally also deal with patents. In practice, however, most cases are heard 
by the PHC. In addition, the Comptroller of the UK Intellectual Property Office may also deal with 
patent infringement disputes, although in practice the Comptroller deals mostly with appeals against 
the UKIPO’s refusal to grant a patent.  
8 In response to concerns that SMEs were less able to avail of patent litigation primarily because of costs 
concerns (Intellectual Property Court Users Committee Working Group, 2009: 6), a  new ‘small claims 
track’ procedure for the PCC, aimed at facilitating claims by SMEs, has recently been proposed by the 
UK Government. It is due for implementation in October 2012 (UK IPO, 2012). Nonetheless, 
Thambisetty states that ‘the proposition that SMEs face an unmet need for a less expensive forum to 
litigate’ is not without its critics (2010: 143). 
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Wales, appeals are made from the PHC to the Court of Appeal (CA). Leave to 
appeal must be granted by the PHC or by the CA itself. Regarding leave to appeal, 
a recent study (Freshfields 2011: 3) notes: 
 
“In principle, this will be granted only where there is a real prospect of 
success or there is another compelling reason – for example, a point of public 
interest. In practice, however, the Patent Court will normally grant leave to 
appeal and will almost always do so if it orders a patent to be revoked.” 
 
The three-person panel at the Court of Appeal is generally not entirely composed 
of IP specialists, although it usually contains one IP specialist. The decision of the 
CA can be challenged at the Supreme Court (formerly the House of Lords). Once 
again, leave must be given for appeal to the Supreme Court (SC), either by the CA 
or the SC itself. According to the Judicial and Court Statistics 2008, the number of 
IP related cases heard by the House of Lords/Supreme Court is typically negligible 
– there were none in 2006, there was only one out of 45 total cases in 2007, and 
only one out of 74 total cases in 2008 (Judicial and Court Statistics 2008; see also 
Section 5.2.2). This makes cases that proceeded to the Supreme Court especially 
interesting as they usually involve legal questions of fundamental character that 
can have a direct effect on future court cases. 
 
3.2 THE CHRONOLOGY OF A TYPICAL PHC CASE 
 
The process of litigation at the PHC is guided by the UK Civil Procedure Rules 
(CPR). The structure and timeline of a patent case is illustrated by Figures 1 and 2. 
Every claim begins with a ‘claim form’ in accordance with CPR part 7.2, which 
must be served within four months of issue, or six months if service is out of the 
jurisdictions under CPR part 7.5. After the claim form is served, the defence has 
to be filed.9 The claimant must apply for a case management conference (CMC) 
within 14 days of the date when all defendants who intend to file and serve a 
defence have done so.10 At the CMC, directions may be given with regard to 
disclosure of information or experiments, and a full hearing date is usually set. 
Given the various time limits for action, cases filed before the PHC often 
take a year or more to make it to full trial. The most recent Freshfields study 
(2011: 6) notes that 12 months is the average wait for a large case to reach full 
trial. Furthermore, the study notes that urgent cases can sometimes reach trial 
within six months and smaller cases can be expedited if necessary. Following the 
                                                     
9 Under CPR part 15.4 the general rule is that the period for filing a defence is either (a) 14 days after 
service of the particulars of claim; or (b) if the defendant files an acknowledgment of service under Part 
10, 28 days after service of the particulars of claim. There is a modification to rule 15.4(1)(b) in CPR 
part 63.7 – regarding a claim for infringement under rule 63.6, the period for filing a defence where the 
defendant files an acknowledgment of service under Part 10 is 42 days after service of the particulars of 
claim. 
10 CPR part 63, Practice Direction 5.3. 
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conclusion of a full hearing, a first-instance judgment will usually be handed down 
within 3-6 months (Freshfields 2011: 1). 
If a claimant in the case believes that there is no realistic prospect of the 
defence succeeding, an application for summary judgment can be made. A hearing 
for summary judgment ‘can take place within six weeks of commencement of the 
action’ (Freshfields 2011: 10). However, due to the complexities involved in patent 
claims concerning the issues of validity and infringement, summary judgments are 
said to be rare (Freshfields 2011: 10), which is also supported by our data. 
In April 2003, a streamlined procedure was introduced with the aim of 
speeding up litigation and reducing associated costs. The key differences between 
the normal and streamlined procedures are: (a) no disclosure, (b) no experiments, 
(c) restriction of cross-examination, and (d) the trial date is fixed when the order 
for a streamlined trial is made (around 8 months from commencement to trial at 
first instance). According to Moore (2006), litigating parties have found the speedy 
process propitious, particularly when they are engaged in multi-jurisdictional 
patent litigation and they seek to use the judgment in parallel proceedings. Parties 
can request the streamlined procedure, or if they fail to do so, and it can be so 
ordered by the court. One objective of the streamlined procedure is to encourage 
the settlement of disputes by means of alternative dispute resolution, such as via 
mediation and conciliation. Moore (2006) claims that the streamlined procedure 
has the drawback that firms have little time to explore outside-court settlement 
options, something which could lead to relatively fewer settlements. 
 
3.3 CHARACTERISTICS OF THE ENFORCEMENT SYSTEM OF 
ENGLAND AND WALES 
 
In this section we discuss a number of characteristics of the legal system in 
England and Wales: 
Firstly, within the common law legal system of England and Wales, lower 
courts are bound by the decisions of higher courts via the system of precedent. As 
noted above, the PHC is part of the High Court of England and Wales, which has 
jurisdiction to deal with civil claims. 
Secondly, the courts in England and Wales deal simultaneous with patent 
validity and infringement, which is a major difference compared for example to 
the legal system in Germany.11 This can have a major impact on the remedies 
granted by courts and the behaviour of litigating parties.12 
                                                     
11 The system in Germany is bifurcated, meaning that validity and infringement are tried by separate 
courts. See Klink (2004) for a discussion of the differences in procedures between the UK and 
Germany. 
12 At a recent House of Commons committee hearing, Henry Carr Q.C. stated that an injunction for 
infringement is more easily obtained in a German court than the PHC precisely because the German 
court grants injunctions before hearing whether a patent is valid (House of Commons European 
Scrutiny Committee, 2012). 
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Thirdly, within the legal system of England and Wales, litigants are 
represented before court by barristers, solicitors, and patent attorneys. Barristers 
have the right of audience in the courts, which means that they are authorised to 
represent litigants in judicial proceedings. They usually do not interact directly with 
clients but instead act exclusively as instructed by solicitors on their client’s behalf. 
Solicitors, in contrast, are in direct contact with clients and thus are authorised to 
act as the client’s attorney.13 Patent attorneys are usually involved in the filing and 
administration of patent applications, the granting of, opposition to, cancellation 
of, or rectification of, patents. Nevertheless, patent attorneys may also represent 
litigants before court. As noted below, this division between solicitors and 
barristers likely has a direct effect on the costs of legal representation in court 
cases. 
Fourthly, unlike other European jurisdictions, such as France where most 
patent cases are infringement cases, it is common for a claimant in a case before 
the PHC to merely argue that a patent is invalid, e.g. due to anticipation or lack of 
inventive step. Alternatively, or in tandem with an invalidity claim, a complainant 
may seek a declaration of non-infringement. In the PHC it is expected that a 
competitor should attempt to ‘clear the way’ before e.g. releasing a product which 
could infringe another company’s patent. If a competitor does not do this, it is 
more likely that the PHC will grant an interim injunction preventing the sale of the 
potentially infringing product upon the commencement of infringement 
proceedings. Cases involving a complainant who alleges infringement and a 
defendant who counter-claims for invalidity are also commonplace. A patentee 
may apply to amend a patent at the PHC. Patent ownership disputes sometimes 
arise, as do licensing disputes.  
Fifthly, with regard to restitution, patent litigation has the objective to 
provide the holder of an infringed IP the right to legal relief. This includes the 
following remedies (Greenhalgh et al., 2010: 50): (a) a (public) declaration that 
what the defendant has been doing is an act of infringement; (b) disclosure of 
information related to the allegedly infringing product; (c) an injunction to stop 
infringement; (d) the delivery or destruction of infringing goods; (e) damages, 
which may be compensatory and which may reflect not only trading losses but 
other forms of damage suffered; (f) receipt of the profits earned by the infringer 
which can be attributed specifically to the infringing act. Typically, an injunction 
may be stayed pending an appeal and ‘an order for revocation is always stayed 
pending appeal’ (Freshfields 2011: 3). With regard to the possibility of obtaining a 
stay of PHC proceedings, it is usually the case that the PHC will not grant a stay 
pending foreign proceedings. However, with regard to EPO opposition 
proceedings, the PHC will sometimes grant a stay, depending on the 
circumstances of the case (Freshfields 2011: 4; see for example the case of Hunt v 
Don & Low14 which is part of our dataset). Depending on the specific facts of each 
                                                     
13 Solicitors may also have the same rights of audience as barristers (so-called Higher Court Advocates). 
However, in practice, in the context of patent litigation there seem to exist very few such advocates. 
14 Hunt Technology Limited v Don & Low Limited [2005] EWHC 376 (Ch); [2005] All ER (D) 61 (Mar). 
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case, the PHC may consider that there are pressing commercial concerns for one 
party within the UK which require an expedited hearing in the UK, rather than a 
delayed one. 
Sixthly, in England and Wales the substantive legal issues and the issues of 
costs and damages are dealt with separately, and the losing party will typically bear 
the brunt of the costs of the case.  Analysis of issues concerning this separation 
between the substantive hearing and the costs hearing, and the subject of the 
allocation of the costs burden is undertaken below at 5.2.3. 
Seventhly, regarding the actual costs of patent litigation at the PHC there is 
little doubt that litigation at the PHC is highly expensive. In 5.2.3. we analyse the 
available costs data as well as recent studies undertaken by Freshfields (2011, 
2007) and Duncan (2010) on the subject of litigation costs at the PHC. 
On the subject of disclosure, an eighth point can be made - within the legal 
system of England and Wales, the disclosure requirement is particularly strong in 
comparison to other European jurisdictions such as Germany. This requirement is 
on-going throughout the duration of the case (Freshfields 2011: 12). In the case of 
litigation concerning process patents, the disclosure requirement is especially 
relevant, in particular with regard to chemicals/pharmaceuticals and ICT. Despite 
this requirement, one party may still dispute the supposed relevance of certain 
information, and there are cases where courts have to rule on whether specific 
disclosure must be made. 
 
 
 
4. DATA 
 
We collected data on all court cases filed between 2000 and 2008 at the PHC, the 
Court of Appeal and the House of Lords/Supreme Court. Due to the possible 
long lag time between the filing of a case and a final decision, in particular if the 
decision rendered by the first instance is appealed, we can only include court cases 
that were filed before 2009 to avoid the presence of a substantial number of 
potentially still pending cases in our dataset. Given our interest in patent litigation, 
we exclude all cases that represent an appeal to an administrative decision taken by 
the UKIPO. We complemented the data with data from court cases heard before 
the PCC (Central London County Court) which we obtained from the UKIPO. 
Because the information on cases at the PCC had to be collected directly from the 
PCC, we only have detailed information on cases heard in 2007 and 2008. 
We collected the data on court cases at the PHC from a range of sources. 
Our starting point was the Patents Court Diary which lists all cases which are 
scheduled for a hearing or an application including, for example, a case 
management conference.15 This means, in principle, the Diary contains all cases 
                                                     
15 http://www.hmcourts-service.gov.uk/cms/list_patents_diary.htm.  
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for which the claim form has been served and to which the defence has 
responded. The Diary provides basic information on court cases, including the 
case number, the names of claimants and defendants (usually only the first 
claimant and defendant), their legal representatives, the date the hearing was fixed, 
as well as the hearing dates and the duration of the hearing. In a number of cases, 
the Diary also notes additional information, such as whether a case was 
discontinued because of a settlement or stay. We use the information from the 
Diary to search for court records on the website of the British and Irish Legal 
Information Institute,16 the case database of Lexis Nexis,17 as well as Thomson 
Reuters’s Westlaw database.18 However, these sources did not offer any records 
for a number of cases (mostly those settled at an early stage). For these cases we 
searched additional sources, such as media websites, blogs or the websites of legal 
representatives for information. 
The most basic information that we collected for all cases includes the names 
of all litigating parties, their country of residence (the country in which a firm is 
registered), the type of litigating party (e.g. company, individual, etc.), the year the 
claim form was served, and the type of IPR in dispute. Additional detailed 
information on the case was collected for all court cases that involved a patent. 
The information was collected and input into a standardised format.19 The 
standardised template contains information on the proceedings/decision type, 
litigating parties, the IPR in dispute, the claims made in the case, the relief applied 
for, the outcome/content of the judgment, and any information on the value, 
costs, and potential damages associated with the case. We also include information 
on related cases within the England and Wales jurisdiction as well as abroad if 
mentioned in the available court records. 
While our datasets represent the most comprehensive database gathered so 
far on the subject of patent litigation in the UK,20 at least two caveats are in order. 
Firstly, obviously the court data provides us only with data on cases that have 
made it to court. Relying on the court diary, however, means that we only observe 
cases that not only have been filed to the court, but were allowed to proceed at 
least to the case management stage. There is no information available on the 
number of cases that are dropped between the serving of the claim form and the 
case appearing on the diary. However, informal conversations we conducted with 
practitioners lead us to believe that this figure is negligible. Secondly, since we had 
to assemble the information with regard to each court case, often relying on 
different sources, in many cases the available court records are incomplete. For 
example, while we may have the judgment of the PHC, we may not have records 
for all preceding applications. This implies that part of the analysis is limited to a 
core set of variables which we were able to obtain for all cases. However, the 
                                                     
16 http://www.bailii.org.  
17 http://www.lexisnexis.co.uk.  
18 http://www.westlaw.co.uk.  
19 The standardised case template was created in collaboration with Ulrike Till. 
20 The data used by Moss et al. (2010) only contain court cases between January 2008 and August 2009 
heard by the Patents County Court, the Patents Court, the Court of Appeal, and the House of Lords. 
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investigation of certain specific aspects of patent litigation, such as the issue of 
costs, focuses on the subset of court cases for which more detailed information is 
available. 
As part of our analysis we combine the information obtained from court 
records with detailed information on the parties as well as the specific patents 
involved in the law suits. The names of the litigating parties were matched to 
Compustat, Bureau van Dijk’s FAME and AMADEUS, and the ICC British 
Company Directory databases in order to obtain information on firms’ 
characteristics and financials. Detailed information on the litigated patents was 
obtained from EPO’s Espacenet and PATSTAT (version October 2011). We also 
draw on PATSTAT to construct a control sample of patents that have not been 
litigated. The control sample consists of non-litigated patents that share the same 
priority year, priority filing authority, and IPC subclasses with litigated patents. 
This control sample allows us to compare the characteristics of litigated patents 
with those of patents that were not subject of litigation at the invention level (the 
priority filing). 
 
 
 
5. ANALYSIS AND RESULTS 
 
In this section, we show descriptive evidence on court cases before the different 
courts in England and Wales, principally distinguishing between activity at the 
PCC and the PHC. We also include a discussion of cases that were heard by the 
House of Lords due to the potentially wider importance of these judgments on 
litigation behaviour before the courts in England and Wales. This section also 
contains a discussion of costs involved in litigation. 
 
5.1 LITIGATION AT THE PATENTS COUNTY COURT 
 
As described in Section 4, we only possess detailed information on litigation at the 
PCC for the years 2007 and 2008. Table 1 shows the total number of cases that 
came before the PCC in these two years and provides an overview of the type of 
IPR that was at dispute. There were a total of 64 IP-related cases in 2007 and 
2008. Less than a fifth of these cases involved a patent; most cases (42%) centred 
on a trademark dispute, followed by cases which primarily involved copyright and 
then cases which focused on (un)registered designs. Hence, patents are the least 
litigated type of IP at the PCC. This is most likely explained by the higher 
complexity of cases involving patented technology and the resulting higher cost of 
litigation, making the PHC relatively more attractive than the PCC for patent 
cases. Potential damages may also be more important in cases involving patents.21 
                                                     
21 Nonetheless, the recent case of Apple enforcing its registered Community Design against its 
competitor Samsung on Samsung’s Galaxy tablet computer shows that the potential infringement of 
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Table 2 explores the characteristics of the patent cases, that is, we limit the sample 
to the 12 cases that involve a patent. The table shows the number of claimants and 
defendants and cross-tabulates this with information on the nationality and type of 
litigant. The first point to note is that the cases involve few parties (as will become 
clear when we describe the cases before the PHC). In all except one case there is 
only a single claimant. The claimants are all companies and either registered in the 
UK or abroad, i.e. there is no case that involves a UK and international claimant 
(which is rather the rule than the exception before the PHC, as noted below).  The 
number of defendants ranges from one to three, where most cases involve two 
defendants. In three cases, the defendants include individuals. 
While this is not shown in the table, all patent cases are about the 
infringement of the patents in question. Half of all cases ended with a judgment, 
where five out of the six cases that ended with a judgment were decided in favour 
of the claimant(s). The other six cases were settled, dismissed, or discontinued. 
Figures 3 and 4 as well as Table 3 examine the characteristics of the 13 
litigated patents (one case covers two patents).22 Figure 3 shows the age 
distribution of the litigated patents; age is computed as the difference between the 
priority year of a patent and the year in which the law suit started. Most patents are 
fairly young at the beginning of the law suit with priority years for seven out of 13 
patents ranging between 2000 and 2005. Figure 4 shows the technologies covered 
by the litigated patents. We constructed technology classes by mapping patents’ 
IPC codes into technologies based on a concordance table.23 The figure shows 
that few patents cover chemical and pharmaceutical patents, whereas most patents 
concern inventions related to mechanical engineering.24 The lack of patents on 
pharmaceutical or ICT related inventions reinforces the view that these patent 
disputes are of lower value, and due to the mostly mechanical nature of the 
underlying inventions most likely also easier to resolve. Table 3 supports the view 
that most patents are of lower value as the median number of forward cites (as of 
April 2012) is zero with only four out of 13 patents reporting a positive number of 
forward citations. We also possess some direct estimates of the value of a number 
of the disputes. The values range from £5,000 to £100,000, with most cases 
located at around £50,000. The relatively low value of these cases is also shown by 
the information on cost orders that is available for two cases, for which costs 
awarded amount to only £10,000.  
Finally, we also take a closer look at the characteristics of the litigating 
companies. Table 4 shows the distribution of companies across industries. Note 
                                                                                                                                       
other forms of IP can have important effects even on such high-tech products as a handheld 
computer. Yet, cases that involve IP other than patents of such importance are also brought before the 
PHC instead of the PCC, as is also the case with Apple vs Samsung (HC11C03010). 
22 Note that one patent was litigated twice in separate cases. For the purpose of these simple descriptive 
statistics we allow the patent to appear twice in our dataset. 
23 The concordance table that maps IPC class symbols to technology categories was developed by the 
Fraunhofer ISI and the Observatoire des Sciences et des Technologies in cooperation with the French 
patent office (see Schmoch, 2008). 
24 The “Other” category contains mostly patents related to civil engineering. 
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that the table only shows UK companies for which a minimum of firm-specific 
information is available.25 Table 4 shows that most companies are involved in 
business services. Others include companies within the metals and machinery 
sectors, which accords with the information on technologies displayed in Table 2. 
Surprisingly, there are a substantial number of large companies, although closer 
inspection of the data (not shown in Table 4) reveals that six out of the eight large 
companies are defendants. Small companies clearly dominate the claimant category 
with six out of nine claimants being in the small size category. The table also 
contains some information on the age of the litigating companies; the main insight 
that emerges from the age distribution is that most firms are well-established and 
there is no significant difference in the age distribution between claimants and 
defendants (not shown in Table 4). 
 
5.2 LITIGATION AT THE PATENTS COURT, COURT OF APPEAL, 
AND HOUSE OF LORDS (SUPREME COURT) 
 
Table 5 shows the number of cases at the Patents Court by year, where year refers 
to the starting date of the initial claim in the case. The average number of cases per 
year is 45 with little variation over time (the median is 46 cases). Patents are by far 
the most litigated IP accounting for over 60% of all cases. Nevertheless, an 
average number of 28 patent cases per year indicates that patent litigation in court 
is an extremely rare event considering that even leaving the EPO aside, the 
UKIPO alone granted more than 2,000 patents in 2008 (UKIPO Facts and 
Figures 2008). Within the scope of PHC cases, (un)registered design rights 
represent the second most important IP category, featuring in about 6% of all 
cases and trademarks account for 4% of cases with a median number of only two 
cases per year.26 Regardless of the IP right at dispute, there is no visible trend in 
litigation behaviour over time with the number of law suits remaining steady over 
the nine years observed (possibly with the exception of cases involving trade 
secrets). 
 
5.2.1. PATENT CASES 
 
We limit the data for our detailed analysis to court cases that involve a patent-
related dispute, which reduces the total number of cases to 255 (see Table 5). Our 
analysis looks at patent cases from three different angles: litigant-level, patent-
level, and case-level.  
Table 6 looks at the characteristics of the litigating parties. The table shows a 
cross-tabulation of the number of claimants and defendants and their nationality 
                                                     
25 No data could be found for four UK based companies (in part because they are not registered with 
Companies House). 
26 Our data do not include High Court cases which involve trademarks or other IP rights, but which do 
not come within the scope of the PHC. 
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and type. There is a maximum of five claimants and twelve defendants. The 
median number of claimants and defendants is one, and the corresponding 
average numbers are 1.3 and 1.6 respectively. The table shows that there are more 
foreign claimants and defendants than UK companies. Cases that involve more 
than a single claimant or defendant frequently involve a mix of domestic and 
foreign companies. This is often explained by the foreign holding joining the 
domestic subsidiary in the lawsuit. There are also cases where a domestic importer 
of a potentially infringing product is joined by the foreign manufacturer of the 
product. The table distinguishes between two types of litigants: registered 
companies and others, where the “other” category includes individuals, non-for-
profit organisations, government, the European Central Bank, and universities. 
Nearly all cases solely involve private companies. Interestingly we observe 
relatively more non-business entities appearing as claimants without a company as 
a co-claimant, than in a case in which they are defendants. In other words, 
individuals and universities are more likely to appear as co-defendants together 
with private companies than to be sued on their own.  
Table 7 is based on the matched firm-level data, i.e. the names of companies 
that were matched to UK, European, and US firm-level data.27 We use the firm-
level data to create size categories and to tabulate these size categories across 
industries. The table shows that the by far largest number of firms is in the 
chemical and pharmaceutical industry (32%), followed by high-tech (18%) and 
metals and machinery (12%).28 The cross-tabulation with firms’ size shows that 
about 60% of firms are large (conditional on firms reporting employment data that 
we require to compute a firm’s size category). There are relatively few small firms 
(<20%); most small firms are in the trade and high-tech sectors. 
Figures 5 and 6 look at the characteristics of the litigated patents.29 Figure 5 
plots the age distribution of the patents (age is computed as the difference 
between the priority year of a patent and the year in which the law suit was 
initiated). The histogram shows that most patents are between six and ten years 
old; few patents are subject to litigation within five years after the priority date. 
There are also a few patents which are older than 20 years; these cases concern 
disputes over the validity of SPCs or disputes over infringement which allegedly 
occurred before the expiration of the patent. Figure 6 shows the frequency of the 
technologies protected by the litigated patents (see Section 5.1 for an explanation 
how we mapped patents into technology classes). The figure shows that chemical 
and pharmaceutical patents are most frequent, followed by patents concerning 
mechanical and electrical engineering.  
                                                     
27 We do not have any firm-level data for non-European/non-US companies. 
28 High-tech is defined as SIC2 30 (Office Machinery and Computers), 31 (Electrical Machinery and 
Apparatus), 32 (Radio, Television and Communication Equipment and Apparatus), and 33 (Medical, 
Precision and Optical Instruments, Watches and Clocks). 
29 We have 210 patents for 160 cases. Patent numbers were not available in all other cases. Note that we 
were able to find only 209 of these 210 patents in PATSTAT. Hence, all statistics that are based on 
PATSTAT data are limited to 209 patents.  
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To gain more insight into the characteristics of the litigated patents, we 
construct a control sample of patents that have not been subject to litigation and 
which have been matched to the set of litigated patents based on the year and 
authority of the priority filing and the IPC subclasses of litigated patents (see 
Section 4 above). Table 8 shows a comparison of a number of patent 
characteristics that are commonly associated with the value of a patent between 
the litigated patents and the control sample.30 The table shows that the number of 
citations received worldwide (as of October 2011) by litigated patents by far 
exceeds that of non-litigated patents. This measure is commonly considered as a 
proxy for patent value and thus suggests that litigated patents are more valuable 
than non-litigated patents.31 Similarly, the family size of litigated patents is 
considerably larger than that of non-litigated patents, which corroborates the 
evidence that litigated patents are more valuable than non-litigated patents.32 The 
comparison of the number of inventors listed on the patent shows that litigated 
patents have slightly fewer inventors. This is surprising if we interpret it as a 
measure of the amount of resources invested in the patented invention.33 We also 
include two variables in our comparison that allow us to gauge the extent to which 
the patented invention is derivative of previous inventions. This is captured by the 
number of backward citations as well as the number of references to the non-
patent literature. The number of non-patent references can also be interpreted as a 
proxy for closeness to (academic) research. These measures suggest that litigated 
patents are more derivative of existing patents and closer to science as reflected by 
the higher non-patent literature reference count. We also include a rough proxy 
for the breadth of a patent by counting the number of IPC subclasses. This 
comparison shows that litigated patents are broader than non-litigated patents. 
While the count of IPC subclasses is an imprecise measure of patent scope, the 
comparison still supports the received wisdom that patents with a broader scope 
are more easily infringed and hence also more likely the target of invalidation 
procedures. We also restrict the control sample to patents that belong to the 
companies that own any of the litigated patents (lower panel of Table 8). The 
results are very similar and thus support the findings for the whole control sample. 
The bottom line of this comparison is that litigated patents are indeed very 
different from comparable (at the invention-level) patents that have not been 
involved in litigation, even when compared to other patents held by the same 
                                                     
30 The measures in Table 8 capture patent value rather than quality. While there is no single definition of 
patent quality in the literature, the existing definitions regard patent quality as the degree to which a 
granted patent satisfies the legal patentability requirements at a given patent office and is likely to 
withstand invalidity proceedings in court or before an administrative body (see Wagner, 2009; Graf, 
2007). Hence, patent quality can be expected to correlate positively with patent value; patent value, 
however, is determined by a much broader range of factors than patent quality which are reflected in 
the different measures employed in our comparison. 
31 See for example Hall et al. (2000). 
32 See for example Lanjouw et al. (1998). 
33 See for example Sapsalis et al. (2006) who find the number of inventors to be positively correlated with 
patent value. 
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firms. They are more valuable, broader, and contain more backward cites and 
references to the non-patent literature.34 
In Tables 9, 10, and 11, we look at the characteristics of the law suits and 
their outcomes. Table 9 shows that only half of all cases are decided by judgment. 
Among the cases that ended without a final judgment, 56% were settled. While we 
do not specifically investigate the effect that the introduction of the streamlined 
procedure in 2003 has had on the propensity to settle, we do observe a drop in the 
number of settlements of cases filed between 2004 and 2006, although the number 
of settlements recovered from 2007 onward (not shown in Table 9). The table also 
provides a rough estimate of the average and median duration of the patent cases. 
The median number of years for a case to end with a judgment is three; we find a 
median of two years for cases that end without final judgment.35 In Table 10, we 
show a cross-tabulation of the case outcome and the number of claimants and 
defendants in a given case. The table offers some evidence to suggest that cases 
that are characterised by a single claimant and/or a single defendant are less likely 
to end with a final judgment than cases with multiple claimants and/or 
defendants. Moreover, cases with more than three claimants mostly settled 
whereas cases with more than three defendants to an overwhelming extent ended 
with a judgment. Finally, Table 11 shows the issue at dispute as well as the 
corresponding outcomes. The largest share of cases for which we have 
information on the claim concerns the infringement of a patent (43%). 
Nevertheless, the share of revocation cases is substantial (31%). In most cases, the 
defending party counter-sues either for revocation in case of an infringement 
action, or infringement in case of an invalidation action (this explains why for 
example in the “infringement row”, the “revoked” cell contains a positive 
percentage). There is a small share of cases (11%) in which other patent-related 
claims are at dispute, such as patent entitlement or the amount of royalty fees due. 
The cross-tabulation with the eventual outcome of the case shows that in fact the 
by far most common outcome is the revocation of a patent. Infringement of a 
valid patent is found only in 15% of all infringement cases that end with a 
judgment, and in 4% of all revocation cases that end with a judgment. Settlement 
ratios do not differ between infringement and revocation suits (both around 25%). 
Finally, we take a look at appeals. Figure 7 shows the share of PHC cases that 
proceed to the next higher instance, that is the Court of Appeal and in rare 
instances the House of Lords. The figure shows that there are proportionally more 
appeals for revocation actions (39%) than for infringement actions (30%).36  
Overall, a third of cases at the PHC proceed to the CA; the share of cases that 
                                                     
34 These findings accord with previous findings in the literature. Cremers (2004), for example, finds 
litigated patents in Germany to have more forward and backward cites as well as a larger family size. 
For USPTO patents, Chien (2011) also finds litigated patents to have more forward cites than non-
litigated patents. 
35 The duration is computed as the difference between the year in which the claim form was issued and 
the year in which the final judgment was given or the court case ended for other reasons such as a 
settlement. 
36 Note that appeals are limited to the set of cases that have ended with a judgment in the first instance. 
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proceeds to the House of Lords, in contrast, is tiny. As will be discussed in detail 
in the next section, only five cases were admitted to be heard before the House of 
Lords. We also have information on whether the CA upheld the judgment of the 
PHC. In nearly 80% of the cases heard by the CA, the court upheld fully or at 
least partially the judgment of the PHC. There is no discernible difference between 
revocation and infringement actions in the share of PHC judgments upheld by the 
CA. The next section takes a closer look at the cases that were heard by the House 
of Lords. 
 
5.2.2. HOUSE OF LORDS/SUPREME COURT CASES  
 
During the period 2000-2008, of cases filed at the PHC only five were heard on 
appeal at the House of Lords/Supreme Court.37 These were all cases involving 
important points of patent law. Two cases, Sabaf v MFI38 and Conor v Angiotech,39 
concerned the test for obviousness. One case, Synthon v Smithkline Beecham40 
concerned the test for novelty. One case, Generics v Lundbeck,41 was primarily 
concerned with the interpretation of 'insufficiency'. The final case, Eli Lilly v 
Human Genome Sciences,42 involved analysis of the criterion of 'industrial 
application'. In this section we discuss each case in detail. 
Sabaf v MFI - The case hinged upon an analysis of the ground of obviousness 
with regard to 'collocation' - the question of whether two unrelated features could 
amount to an inventive step. The PHC noted that merely placing old integers side-
by-side so that each performed its own function independently of the other did 
not amount to a patentable invention. The PHC therefore revoked Sabaf's patent 
for a gas burner. The CA overturned the High Court's finding of invalidity and 
found the patent to be valid, stating that the Patent Act 1977 did not refer to 
collocation. However, the House of Lords reversed the decision of the CA, 
reaffirming the existence of a law of collocation in UK law and noting that this 
was in accordance with EPO reasoning. In the House of Lords, Lord Hoffmann 
                                                     
37 The House of Lords case Kirin-Amgen, Inc. and Others v. Hoechst Marion Roussel Limited and Others [2004] 
UKHL 46; [2005] R.P.C. 9 does not form part of the study since the case was filed in 1999. 
38 Sabaf SpA v MFI Furniture Centres Limited and others; Sabaf SpA v MFI Furniture Centres Limited and others 
(Conjoined Appeals) [2004] UKHL 45; [2005] RPC 10; on appeal from [2002] EWCA Civ 976; [2003] 
RPC 14; accessible at http://www.publications.parliament.uk/pa/ld200304/ldjudgmt/jd041014/sabaf-
1.htm. 
39 Conor Medsystems Incorporated v Angiotech Pharmaceuticals Incorporated and others [2008] UKHL 49; [2008] 
R.P.C. 28; on appeal from [2007] EWCA Civ 5; [2007] RPC 20; accessible at 
http://www.publications.parliament.uk/pa/ld200708/ldjudgmt/jd080709/conor-1.htm.  
40 Synthon BV v Smithkline Beecham plc [2005] UKHL 59; [2006] R.P.C. 10; on appeal from [2003] EWCA 
Civ 861; [2003] R.P.C. 43; accessible at 
http://www.publications.parliament.uk/pa/ld200506/ldjudgmt/jd051020/synth-1.htm.  
41 Generics (UK) Limited and others v H Lundbeck A/S [2009] UKHL 12; [2009] R.P.C. 13; on appeal from 
[2008] EWCA Civ 311; [2008] R.P.C. 19;  accessible at 
http://www.publications.parliament.uk/pa/ld200809/ldjudgmt/jd090225/gener-1.htm.  
42 Human Genome Sciences Inc v Eli Lilly and Company [2011] UKSC 51; on appeal from [2010] EWCA Civ 
33; [2010] R.P.C. 14; accessible at http://www.supremecourt.gov.uk/decided-
cases/docs/UKSC_2010_0047_Judgment.pdf.  
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noted that before undertaking an analysis of obviousness it was necessary to 
consider what the invention consisted of - two inventions would not become one 
invention merely because they were included within the same hardware. Regarding 
obviousness, the House of Lords held that because the two features did not 
interact, it was necessary to evaluate each one separately, and in this case neither 
one was inventive. 
Synthon v Smithkline Beecham - The crucial legal point in this case concerned the 
concept of 'enabling disclosure' - the vital element for determining the novelty 
requirement. Smithkline Beecham held a patent for a pharmaceutical compound 
called paroxetine which was used in the treatment of depression. Synthon sought 
revocation of the patent on the basis of lack of novelty. The PHC had found the 
patent to be invalid due to lack of novelty, but this was overturned by the CA 
because the disclosure did not give clear and unmistakable directions to make the 
compound. Nonetheless, the House of Lords reversed the decision of the CA and 
found that the patent had been anticipated. The House of Lords noted that within 
the criterion of 'enabling disclosure' there was a distinction between 'disclosure' 
and 'enablement'. Furthermore, in assessing the adequacy of the enablement it can 
be assumed that the skilled person would use his skill as appropriate to the 
technical field, which in this case including making some 'trial and error' 
experiments. 
Conor v Angiotech - In this case Conor sought revocation of Angiotech's patent 
for a stent coated with taxol on the basis of obviousness. Both the PHC and the 
CA found the patent to be obvious because at the time of the disclosure, the 
patentees had not known for certain that the taxol coating would have the desired 
effect. The parties then settled in 2007, before the appeal was due to be heard 
before the House of Lords. Nevertheless, Angiotech sought to have the judgment 
overturned. In order for the hearing to take place, notwithstanding the settlement, 
Angiotech agreed to pay for counsel to argue Conor’s side of the argument. The 
House of Lords stated that the patent was not obvious and therefore was valid. All 
that was required with regard to obviousness was that the proposed invention was 
plausible at the priority date, and that it did in fact work. The following was noted 
by Lord Hoffmann in Paragraph 39 of the judgment: 
 
"But there is in my opinion no reason as a matter of principle why, if a 
specification passes the threshold test of disclosing enough to make the 
invention plausible, the question of obviousness should be subject to a 
different test according to the amount of evidence which the patentee 
presents to justify a conclusion that his patent will work [...]" 
 
Generics v Lundbeck - The case primarily concerned the application of the ground of 
'insufficiency' with respect to the validity of a granted patent related to the anti-
depressant drug Escitalopram. The House of Lords affirmed the decision of the 
CA that a product patent ought not to be revoked on the ground of insufficiency, 
even where the actual inventive step was in the method by which the product 
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could be made. The House of Lords distinguished on the facts its previous 
decision in Biogen v Medeva, a case which did not involve a pure product claim, but 
a class of products. The House of Lords therefore clarified the circumstances in 
which a patent ought to be revoked due to insufficiency. 
Human Genome Sciences (HGS) v Eli Lilly - This Supreme Court case centred on 
the interpretation of 'industrial application' under Art.57 EPC and the application 
of this criterion to biotechnology patents. Eli Lilly sought revocation of a HGS 
patent covering the gene and protein sequences of a protein known as 
Neutrokine-α on the ground that HGS had not specified a use for the protein 
which was capable of industrial application. The Supreme Court overturned the 
decisions of the High Court and Court of Appeal, who had stated that the patent 
lacked industrial application. Referring to EPO Technical Board reasoning, the 
Supreme Court took a relaxed view of 'industrial applicability' with respect to gene 
patents and emphasised that the UK courts ought to follow the EPO decisions in 
this area. Specifically, the Supreme Court stated that there was no need for a 
disease indication to be identified for there to be industrial applicability. 
All of the above cases featured points of law which required an assessment by 
the House of Lords/Supreme Court. Sabaf v MFI found the court making an 
important ruling on the relationship between ‘collocation’ and inventive step. 
Synthon v Smithkline Beecham saw the court re-defining the concept of enabling 
disclosure as containing two requirements – ‘disclosure’ and ‘enablement’. Conor v 
Angiotech re-emphasised that the test for obviousness ought to assess the 
‘plausibility’ of the invention as an important consideration. In Generics v Lundbeck 
the court distinguished the present case from one of its previous rulings, clarifying 
the extent to which ‘insufficiency’ applies to pure product claims as opposed to 
classes of products. In Human Genome Sciences v Eli Lilly, the SC ruling sought to 
bring UK jurisprudence concerning ‘industrial application’ in line with EPO 
rulings. 
 
5.2.3. ASSESSING THE COSTS OF TAKING A CASE AT THE PATENT 
HIGH COURT 
 
It is generally acknowledged that the costs of taking a patent case at the PHC are 
substantial. A recent report on civil litigation costs authored by Jackson L.J. (Final 
report, 2009: 250) quotes Dietmar Harhoff’s comments on patent litigation costs 
within the EU (Final report, 2009: 250, referring to a paper by Harhoff presented 
at the IP forum) in order to summarise the conventional view on the costs 
involved in patent enforcement in the UK: 
 
“The UK system is the most costly one, and this aspect is generally noted as 
negative. Costs are also considered to be a decisive factor in generating a large 
number of settlements in the UK system.” 
 
  
Christian Helmers and Luke McDonagh                                               Patent Litigation in the UK  
 
 21
As stated above, in England and Wales the substantive legal issues and the issues 
of costs and damages are dealt with separately. However, not all cases proceed 
post-trial to a full hearing on costs. In fact, in most cases parties settle the issue of 
costs once a judgment has been handed down (Freshfields, 2007; 1). For this 
reason, detailed cost hearing court records are not available for most PHC cases.43 
Nonetheless, it is possible based on the records found with regard to cases filed 
during the period 2000-2008 to extrapolate some figures and case studies which 
can illuminate the issue of costs. Before the costs data can be discussed, it must be 
noted that under CPR section 44 the unsuccessful party is required to pay the 
other party’s costs. However, in the context of patent litigation, it is often the case 
that this rule is not strictly applied. On this point, Floyd J. states:44 
 
“In patent cases, an issue-based approach to costs is now the norm: see 
Smithkline Beecham v Apotex [2004] EWCA Civ 1703 ; Actavis v Merck 
[2007] EWHC 1625 (Pat); Generics v Lundbeck [2007] EWHC 1606 (Pat) 
and Monsanto Technology v Cargill International [2007] EWHC 3113 (Pat).” 
 
Similarly, Goldberg (2010; para. 2) notes: 
 
“In patent cases, the courts have deviated from the spirit of section 44 by 
granting parties costs only on the issues they have won. Generally, 
infringement claims are separate from invalidity. Both infringement and 
invalidity claims may be further itemised in terms of the various arguments 
advanced. Consideration is given to the general victor in commercial terms, 
the reasonableness of the issues argued, and the behaviour of the parties.” 
 
Nonetheless, as a general rule it is the case that the losing party will usually bear 
the majority of the costs of the case. It is often the case that the successful party 
will recover about two-thirds of its legal fees, depending on how the issues were 
won and lost (Freshfields 2011: 8). Furthermore, once a party has lost on 
substantive grounds, the party may decide to ‘cut his losses’ and to settle out of 
court regarding the actual amount of costs and damages. For this reason, it is 
often the case that there are no court records available regarding the specific 
amount of costs and damages allotted to each side in each case. It is usually the 
case that it is only where the parties have been unable to ‘settle’ these issues that 
there will need to be a court hearing on costs or damages. Consequently, the 
                                                     
43 Unless the costs are agreed between the parties, once the trial judge has made cost orders at the PHC 
costs hearing, the details of the costs themselves are usually ‘assessed separately by a costs judge (who 
does not have specialist patent knowledge) for reasonableness in detailed assessment (typically recovery 
is around 70%)’ (SJ Berwin, 2009; 1). It is important to note that the costs data discussed in this article 
are the ‘pre-assessment costs’, or ‘gross’ costs, before any separate assessment by a costs judge has 
taken place. 
44 See costs hearing in Research in Motion UK Ltd v Visto Corporation; Visto Corporation v Research in Motion & 
Anor [2008] EWHC 819 (Pat), at para. 6; costs hearing undertaken following full trial [2008] EWHC 
335 (Pat); [2008] Bus. L.R. D89. 
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analysis of the costs/damages data undertaken here is based upon an evaluation of 
the records which are available, in conjunction with analysis of previous studies, 
including the Freshfields studies (2007, 2011). 
Regarding specific cost sums, Jackson L.J. reviewed a small sample of 15 IP 
cases between 1999 and2007 ‘settled or taken to first instance trial by a leading IP 
department from a City law firm’ (Final Report, 2009: 24). The sample reviewed 
the costs data from the point of view of one firm representing the claimant in 10 
cases and the defendant in 5 cases. The costs data is therefore applicable only to 
one side of the dispute. The sample was comprised of 12 patent cases, 2 trademark 
cases and 1 design case (Final Report, 2009: Appendix 3). Within this sample of 15 
IP cases, 3 patent cases were settled at an average cost of approximately £870,000 
per case (Final Report, 2009: Appendix 3). Of the 12 remaining IP cases which 
reached a judgment, 9 of which were patent-related, the average cost was 
approximately £650,000, with the cost ranging from £200,000 to £1.2million 
(Final Report, 2009: Appendix 3). With respect to the reasons behind these high 
costs, Jackson L.J. (Final report, 2009: 24) notes: 
 
“The costs incurred from the start of trial to judgment or settlement averaged 
nearly 20% of the total costs of the cases. The trial costs were a large 
proportion of the total costs due to the cross examination of the expert 
witnesses.” 
 
Freshfields (2011: 8) note that if a patent case goes for a full hearing at the PHC, 
the total costs, accommodating the costs of both sides, will on average amount to 
£3 million i.e. £1.5 million for each side. A more conservative estimate is put 
forward by Duncan (2010; para. 10), who states that it is common for PHC cases 
to cost ‘in the region of £200,000 to £500,000 for straight-forward cases’, noting 
further that it can cost ‘up to and more than £1,000,000 for complex cases’. Our 
data on patent cases heard between 2000 and 2008 is supportive of the higher 
figures suggested by Freshfields (2011). While there are a few cost orders in the 
region of £50,000-100,000 that concern hearings on specific applications rather 
than a full trial that ended with a judgment, most cases that ended with a 
judgment, and for which we have data, report total costs in the region between 
£1million and £6million.45 Reasons for the relatively high costs (compared to 
other jurisdictions such as Germany) lie in the specific features of the British legal 
system as noted in the Jackson report (2009) quoted above. In particular, high 
                                                     
45 At the very high end of the costs scale, the costs arising from the joined cases involving Research in 
Motion and Visto  Corporation are of significance - RIM's costs were estimated at nearly £6 million 
while Visto’s costs were estimated at £1.6 million. This case is discussed in greater detail in a 
companion paper (Helmers and McDonagh, 2012). See Research in Motion UK Ltd v Visto Corporation; 
Visto Corporation v Research in Motion & Anor [2007] EWHC 900 (Ch); [2007] EWHC 1921 (Pat); [2008] 
EWHC 335 (Pat); [2008] Bus. L.R. D89; costs hearing [2008] EWHC 819 (Pat); stay application 
appealed to Court of Appeal [2008] EWCA Civ 153 (cases HC06C03912 & HC06C042270). See also 
HC08C02901 - the case of Research in Motion UK Ltd v Visto Corp; Visto Corp v Research in Motion UK Ltd. 
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costs are generated due to the existence of oral hearings, which require the 
expertise of solicitors and the advocacy of barristers, the need for extensive cross-
examination of expert witnesses, as well as the requirements of the on-going duty 
of disclosure of any relevant documents (Freshfields 2011: 8; Jackson L.J. Final 
Report, 2009). 
With regard to specific PHC case studies from our survey, it was noted above 
the case of Eli Lilly and Co v Human Genome Sciences Inc46 eventually reached the 
Supreme Court. However, the available costs data only relate to the PHC hearing. 
Costs following the PHC trial were attributed at £1,380,000 (Eli Lilly) and 
£2,220,000 (Human Genome Sciences Inc). In consideration of the fact that it 
won the main issue at the HC hearing, the court held that the claimant, Eli Lilly, 
was entitled to 60% of its costs of the action (amounting to approximately 
£828,000). Similarly, in Generics v Lundbeck,47 another case which eventually 
reached the Supreme Court, there was a PHC costs hearing. Regarding the 
claimants, Generics' costs were estimated at £886,000, Arrow’s at £554,000 and 
Teva’s at £624,000. Lundbeck, the defendant, estimated its costs to be about 
£1,815,000. Teva and Lundbeck agreed to settle costs, but a hearing was required 
to assess the apportionment of costs between Lundbeck and the remaining 
claimants. The PHC held that costs should be divided 60/40 - Lundbeck was 
ordered to pay to Generics and Arrow 60% of their costs of the trial and Generics 
and Arrow were ordered to pay to Lundbeck 40% of its costs. Given the fact that 
both Human Genome Sciences v Eli Lilly and Generics v Lundbeck  eventually required a 
Supreme Court hearing, it is likely that the level of complexity in both cases was 
unusually high, which could partially explain the high level of costs in these cases. 
Nonetheless, other cases examined below suggest that costs are generally high in 
PHC cases. 
In Apotex v Smithkline Beecham48, which involved two separate cases, there were 
costs hearings at both the PHC and at the Court of Appeal. The PHC trial lasted 
11 days. At the PHC, it was stated that Smithkline Beecham’s total costs up to that 
point amounted to £3,367,918 while Apotex’ costs amounted to approximately 
£2,700,000. At the PHC costs hearing the court ordered Smithkline Beecham to 
pay 76% of Apotex’s costs. However, while the Court of Appeal upheld the 
original PHC decision on non-infringement, it reversed it with regard to validity.49 
With regard to costs, the Court of Appeal then stated that overall Apotex ought to 
have 16% of the costs arising from the first instance PHC case, and Smithkline 
Beecham ought to have 25% of the costs of the appeal. No further specific cost 
                                                     
46 Eli Lilly and Co v Human Genome Sciences Inc [2008] EWHC 1903 (Pat); [2008] R.P.C. 29; costs hearing 
[2008] EWHC 2511 (Pat). 
47 Generics (UK) Limited and others v H Lundbeck A/S [2007] EWHC 1040 (Pat); [2007] R.P.C. 32; costs 
hearing.  
48 Apotex Europe Limited and others v Smithkline Beecham plc and others Smithkline Beecham plc and others v Apotex 
Europe Limited and others [2003] EWHC 2939 (Pat); [2004] F.S.R. 26; costs hearing [2004] EWHC 964 
(Pat). 
49 Apotex Europe Limited and others v Smithkline Beecham plc and others; Smithkline Beecham plc and others v Apotex 
Europe Limited and others [2004] EWCA Civ 1568; [2005] F.S.R. 23; costs hearing [2004] EWCA Civ 
1703; [2005] 2 Costs L.R. 293. 
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amounts were discussed at the Court of Appeal costs hearing. In Abbott 
Laboratories v Evysio,50 Abbott applied for revocation of three of Evysio’s patents, 
and also for declarations of non-infringement with regard to the three patents, 
which related to coronary stents. After a trial lasting 8 days, the PHC costs hearing 
attributed costs of £2.63 million (Abbott) and £1.46 million (Evysio). Costs were 
granted mostly in favour of Abbott, based on the issues it won at the PHC trial, 
which meant that Abbott was granted 75% of its costs (amounting to 
approximately £1,972,500). 
In the case of Generics (UK) Ltd v Daiichi51 there was a PHC costs allocation 
hearing at which it was established that the claimant's costs of taking the case 
through 11 hearing days to a PHC judgment were approximately £1.3 million, 
whereas the defendants’ costs were approximately £3.4 million. The defendants 
had won most of the substantive issues of the PHC case. In the circumstances, the 
claimant accepted that the defendants were entitled to a costs order in their favour 
but submitted (i) that the costs incurred by the defendants were wholly 
disproportionate and should be capped and (ii) that the costs should be reduced to 
reflect the fact that, even though the defendants could be described as being the 
overall winner, the defendants had lost on a number of issues. Regarding the first 
issue, the PHC did not allow the costs to be capped. With respect to the second 
issue, the PHC acknowledged that the defendants had won on most issues and 
were therefore entitled to 88% of their assessed costs of the action. As noted 
above, the defendants’ pre-assessment costs were estimated at £3.4 million (of 
which 88% amounts to approximately £2,992,000). 
In Monsanto v Cargill52 costs were granted by the PHC mostly in favour of 
Monsanto because it won on all claims except the issue of construction of 
infringement. The PHC trial lasted 13 days. Monsanto’s total costs were estimated 
at £2.2million and Cargill’s were stated to be £1.9million. After weighing up the 
issues won and lost, the PHC ordered that a rounded off sum of £800,000 ought 
to be paid by Cargill to Monsanto. In Buhler AG v FP Spomax53 costs were granted 
in part to defendants at the PHC costs hearing Buhler AG were ordered to pay 
40% of FP Spomax 's total costs of approximately £1million (amounting to 
approximately £400,000). In Actavis UK Ltd v Merck54 the PHC made a costs order 
which ultimately favoured the defendant in the case.  The PHC trial lasted 3 days. 
The claimant’s costs were estimated at £500,000, while the defendant’s costs were 
estimated at £600,000. Costs were divided in favour of Merck because it won the 
                                                     
50 Abbott Laboratories Ltd v Evysio Medical Devices ULC [2008] EWHC 800 (Ch); [2008] R.P.C. 23; costs 
hearing [2008] EWHC 1083 (Pat). 
51 Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd; Daiichi Pharmaceutical Sankyo Ltd [2008] EWHC 2413 
(Pat); [2009] R.P.C. 4; costs hearing [2008] EWHC 2958 (Pat). 
52 Monsanto Technology LLC v Cargill International SA; Cargill plc [2007] EWHC 2257 (Pat); [2008] F.S.R. 7; 
costs hearing [2007] EWHC 3113 (Pat). 
53 Buhler AG v FP Spomax SA [2008] EWHC 823 (Pat); [2008] All ER (D) 291 (Apr); costs hearing [2008] 
EWHC 1109. 
54 Actavis UK Ltd v Merck & Co Inc [2007] EWHC 1311 (Ch); [2007] All ER (D) 24 (Jun); costs hearing 
[2007] EWHC 1625 (Pat). 
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issue that the court spent most time on during the trial; although Actavis 
succeeded in getting the patent revoked at the PHC, it lost on the issue of 
obviousness and was ordered to pay these costs. After considering the various 
applicable percentages based on an issue-based approach, the PHC decided to 
make a single net order that Actavis ought to pay Merck a total of £100,000.  
At the lower end of the costs scale, there was a PHC costs allocation hearing 
in Ivax Pharmaceuticals (UK) Ltd v Chugai Seiyaku Kabushiki Kaisha.55 The PHC trial 
lasted for 4 hearing days. Ivax incurred costs totalling £300,000, whereas Chugai's 
costs were estimated at £700,000. Ivax won on most issues so at the costs hearing 
the PHC stated it should have 60% of its costs. In the case of Schlumberger v 
Electromagnetic Geoservices (EMGS) 56 the issue of interim costs was decided at the 
PHC stage. The PHC ordered that £1m ought to be paid by Electromagnetic 
Geoservices to Schlumberger as interim costs of the action. The PHC ruled that 
EMGS should pay 82.5% of Schlumberger's costs of the action – estimated at 
£2.286 million. 
With regard to costs in the context of applications for injunctions or 
amendments, in Hospira UK Limited v Eli Lilly57 a PHC judgment refused Hospira’s 
application for leave to amend, and also refused an injunction to prevent 
commencement of an action. Hospira was ordered to pay the costs of the 
application. The total costs of the application hearing were £76,000. Hospira was 
ordered to pay Eli Lilly a total of £50,000. However, after the substantive matters 
of the case were resolved in Hospira’s favour, Eli Lilly was ordered to make an 
interim payment of £125,000 to Hospira at a later costs hearing to reflect the costs 
expounded by the claimant. In Mayne v Teva UK Ltd58 Mayne lost its application for 
an injunction at the PHC. As a result, Mayne was ordered to pay Teva’s costs for 
the injunction hearing, amounting to £38,500. In Arrow v Merck59 the PHC ruled 
against Merck’s striking out action regarding the negative declaration it sought. 
Merck was seeking to establish that its product was, at the priority date of Merck’s 
claimed patent (which had been applied for but not yet granted), non-inventive (as 
regards the features of the patent applications) and so could not infringe any 
granted patent of the defendant. Following the failure of Merck’s application, 
Arrow sought costs of £65,000–£75,000. However, because Arrow did not 
succeed on every single issue, the PHC awarded the sum total of £35,000. 
 
 
                                                     
55 Ivax Pharmaceuticals (UK) Ltd v Chugai Seiyaku Kabushiki Kaisha [2006] EWHC 756 (Pat); [2006] All ER 
(D) 131 (Apr); costs hearing [2006] EWHC 853 (Pat). 
56 Schlumberger Holdings Ltd v Electromagnetic Geoservices AS [2009] EWHC 58 (Ch); [2009] R.P.C. 19; costs 
hearing [2009] EWHC 773 (Pat). 
57 Hospira UK Limited v Eli Lilly & Company [2008] EWHC 1862 (Pat); costs hearing [2009] EWHC 3001 
(Pat). 
58 Mayne Pharma (USA) Inc; Mayne Pharma Plc; Mayne Group Ltd v Teva UK Ltd; Approved Prescription Services 
Ltd [2005] EWHC 2141 (Pat); [2005] All ER (D) 116 (Oct); interim injunction hearing [2004] EWHC 
3248 (Ch); costs hearing [2004] EWHC 2934 (Pat). 
59 Arrow Generics Limited; Arrow Pharm (Malta) Limited v Merck & Co, Inc [2007] EWHC 2387 (Pat); costs 
hearing [2007] EWHC 1900 (Pat). 
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6. CONCLUSION 
 
We provide the first detailed description and analysis of patent cases heard by the 
Patents County Court (2007-2008) as well as the Patents Court (2000-2008) for 
England and Wales. The data also cover appeals made to the Court of Appeal and 
the House of Lords/Supreme Court.  
Our analysis of the IP cases heard before the PCC indicates that patents are 
the least litigated IP right. Only 12 out of 64 IP cases concluded in 2007 and 2008 
involved a patent. Upon looking further into these 12 patent cases, we find that 
they involve few litigating parties – most cases involved only a single claimant and 
defendant. Interestingly, all patent cases heard by the PCC are about the 
infringement of a patent, whereas only around half of all patent cases before the 
PHC are infringement actions. Our analysis of the patents litigated at the PCC 
shows that these patents are relatively young (most patents are less than 10 years 
old) and overwhelmingly protect inventions related to mechanical engineering. 
This stands in stark contrast to the cases heard by the PHC, where most patents 
protect pharmaceutical and chemical compounds and production processes. The 
mechanical, discrete nature of the inventions protected by the patents litigated at 
the PCC supports the view that patents of lower complexity and value are litigated 
before the PCC. Our data on the value of these court cases supports this further 
with values ranging from £5,000 to £100,000. The litigating parties are mostly in 
the business services and the metals and machinery sectors. It is also noteworthy 
that the vast majority of claimants at the PCC are small firms, whereas there are a 
disproportionate number of large firms among the defendants. 
Our analysis of the court cases brought before the PHC shows that patents 
are by far the most litigated IP right. On average, 28 out of 45 annual cases involve 
a patent. The ratio of patent cases per year has remained remarkably stable 
throughout the nine-year period of our study. In our detailed analysis, we focus on 
the 255 patent cases, out of a total of 407 IP cases.  
In our analysis, we look at characteristics of the litigating parties, the patents 
at dispute, as well as the relevant case-specific characteristics and outcomes. We 
find a substantial number of cases with more than a single claimant and defendant. 
Nevertheless, the median number of claimants and defendants is one. Our data 
also suggest that patent litigation in the UK is a highly internationalised service. 
We have a substantially higher number of foreign than domestic claimants and 
defendants. We also match detailed firm-level data to our case-level data - this 
allows us to look at the characteristics of the registered companies involved in the 
law suits. We find that most companies in our dataset are in the chemical and 
pharmaceutical industry, followed by companies involved in high-tech and metal 
and machinery. This is confirms our analysis at the patent-level which indicates 
that most patents protect chemical and pharmaceutical inventions. 
Looking in more detail at the patents involved in our PHC cases, we find that 
most patents are aged between 6 and 10 years, although we even have a few cases 
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that involve an expired patent. A comparison of the set of litigated patents with a 
sample of non-litigated patents that have been matched at the invention (priority 
filing) level reveals that the litigated patents tend to be different in several respects. 
Litigated patents are more valuable, broader in scope, and also contain more 
references to other patents, and the non-patent literature, than non-litigated 
patents.  
Our dataset also allows us to look at the characteristics of the law suits and 
the corresponding outcomes. We show that only about 43% of all cases are filed 
alleging the infringement of a patent. In fact, around 31% of filed cases seek the 
revocation of a patent. Furthermore, we find that only half of all cases filed end 
with a final judgment. More than half of all cases that did not end with a judgment 
were settled. Cross-tabulating the information on the number of litigating parties 
and the outcome (final judgment yes/no) suggests that cases with a single claimant 
and/or defendant are more likely to settle than cases that involve a large number 
of litigating parties.  
Regarding case outcomes, when we examine the cases which ended with a 
judgment, we find that the most likely outcome by far is the revocation of a patent 
– regardless of whether the case was filed as an infringement or revocation action. 
Finally, we show some evidence on appeals. We find that about a third of all cases 
proceed to the CA, where in 80% of cases the judgment of the PHC is upheld. We 
also provide a detailed discussion of the five cases that were allowed to proceed to 
the House of Lords, all of which featured an important point of law. 
While detailed data on the costs involved in litigation is unavailable for the 
reasons explained in detail in Section 5.2.3, our data allow us, in combination with 
existing anecdotal evidence, to make some tentative statements about the 
magnitude of the costs involved in litigating before the PHC. Our data indicate 
that most cases feature total costs, encompassing costs for both claimant(s) and 
defendant(s), amounting to a sum between £1 million and £6 million. 
In summary, this article provides a first assessment of patent law suits before 
the courts in England and Wales for the period 2000-2008. The above descriptive 
analysis indicates a number of angles from which the data could be analysed 
further in future. 
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Figure 4: PCC – IPC/Technology distribution (patent cases in 2007 & 2008) 
 
Note: Other includes: Furniture & games, other consumer goods, and civil engineering. 
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Figure 5: PHC – Patent age distribution (patent cases in 2000-2008) 
 
Figure 6: PHC – IPC/Technology distribution (patent cases in 2000-2008) 
 
Note: Other includes: Furniture & games, other consumer goods, and civil engineering. 
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Figure 7: Appeals from the PHC (patent cases in 2000-2008) 
 
Note: PHC: Patents Court; CA: Court of Appeal; HL: House of Lords/Supreme Court 
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Table 1: PCC -- Number of cases by year, 2007 and 2008 
Year Cases Patent Trademark 
(Un)registered 
Design Tradesecrecy Copyright Other 
2007 34 7 15 7 na 9 1 
2008 30 5 12 6 na 10 1 
Total 64 12 27 13 na 19 2 
*Sum of cases by type exceeds total of cases (64) because individual cases can involve different types of IPRs 
         
                      
Table 2: PCC -- Characteristics of patent cases, 2007 and 2008 
 
Claimant Defendant 
Number 
of parties 
Nationality Type Nationality Type 
UK Foreign UK/Foreign Firm Firm/Individual UK Foreign UK/Foreign Firm Firm/Individual 
1 7 4 0 11 0 4 0 0 4 0 
2 1 0 0 1 0 4 2 1 4 3 
3 0 0 0 0 0 0 0 1 1 0 
Sum 8 4 0 12 0 8 2 2 9 3 
            
 
            
 
 
Table 3: PCC -- Patent characteristics (2007 and 2008) 
 
 
  Mean Median St. dev. Min Max 
 
 
Backward citations 4.154 4 3.647 0 10 
 
 
Forward citations 0.769 0 1.301 0 3 
 
 
  
  
                
Table 4: PCC -- Litigating companies by sector 
Sector Total Size Age 
    Small Medium Large <10 
≥10 & 
<50 ≥50 
Business services 5 1 0 4 4 1 0 
Chemicals 1 0 1 0 0 1 0 
Construction 2 0 0 2 1 1 0 
Hightech 1 0 1 0 0 1 0 
Metals & machinery 4 3 1 0 0 1 2 
R&D services 1 0 0 1 0 1 0 
Trade 5 4 0 1 1 3 1 
Total 19 8 3 8 6 9 3 
* Only shows data for 19 UK companies for which data was available 
         
                
Table 5: PHC -- Number of cases by year, 2000 to 2008 
Year Patent Trademark 
(Un)registered 
Design Tradesecrecy Copyright Other NA*** 
2000 18 1 0 0 0 3 22 
2001 22 2 2 0 0 1 9 
2002 24 1 1 0 1 2 20 
2003 28 2 2 0 0 1 7 
2004 27 1 1 0 0 1 16 
2005 28 4 6 0 2 0 11 
2006 40 0 6 1 1 0 4 
2007 31 3 3 1 0 0 3 
2008 37 3 3 2 0 2 1 
Total 255 17 24 4 4 10 93 
* Sum of cases by type exceeds total of cases (374) because individual cases can involve different types of IPRs 
** Excludes all cases that involve the UKIPO (appeals of administrative decisions) 
  *** No information found in either court records or other sources 
    
                          
Table 6: PHC -- Characteristics of patent cases, 2000-2008 
 
Claimant Defendant 
Number 
of 
parties 
Nationality Type Nationality Type 
UK Foreign UK/Foreign Firm Other Mixed UK Foreign UK/Foreign Firm Other Mixed 
1 94 106 0 193 7 0 76 95 0 170 1 0 
2 7 9 24 36 3 1 16 15 23 44 1 9 
3 4 1 6 10 0 1 3 1 10 13 0 1 
4 0 0 3 1 0 2 2 1 6 7 0 2 
5 0 0 1 1 0 0 0 2 1 3 0 0 
6 0 0 0 0 0 0 1 0 1 1 0 1 
>6 0 0 0 0 0 0 0 0 2 1 0 1 
Sum 105 116 34 241 10 4 98 114 43 239 2 14 
* Other/Mixed includes individuals, non-for-profit organizations, government, the European Central Bank, and universities 
  
              
Table 7: PHC -- Litigating companies by sector 
Sector Total Size 
  # % Small Medium Large NA 
Business services 25 4.7% 3 3 1 18 
Chemicals/Pharma 171 32.4% 11 16 83 61 
Computer services 24 4.5% 2 2 3 17 
Construction 4 0.8% 1 1 0 2 
FIRE 3 0.6% 0 0 2 1 
Food etc 1 0.2% 0 0 0 1 
Hightech* 94 17.8% 13 11 35 35 
Metals & machinery 64 12.1% 8 8 29 19 
Other mfg 26 4.9% 3 4 7 12 
R&D services 13 2.5% 4 3 2 4 
Textiles & apparel 4 0.8% 0 0 3 1 
Trade 39 7.4% 13 8 8 10 
Transportation 7 1.3% 0 2 2 3 
Wood & paper 6 1.1% 0 1 4 1 
Other services 18 3.4% 2 1 4 11 
Telecommunications 19 3.6% 1 5 4 9 
Petroleum & refining 10 1.9% 0 1 6 3 
Total 528 100.0% 61 66 193 208 
* High-tech includes SIC2 30 (Office Machinery and Computers), 31 (Electrical Machinery and Apparatus), 32 
(Radio, Television and Communication Equipment and Apparatus), and 33 (Medical, Precision and Optical 
Instruments, Watches and Clocks). 
 
                        
Table 8: PHC -- Comparison litigated vs non-litigated patents 
 
Mean Std. Dev. T-test* Min Max # Obs.  
Litigated Control Litigated Control difference Litigated Control Litigated Control Litigated Control 
All control patents 
Backward citations 3.49 0.76 3.99 1.99 -19.36 0 0 21 61 209 17,343 
Forward citations 10.06 1.67 21.69 8.13 -14.32 0 0 161 524 209 17,343 
Non-patent references 1.83 0.46 3.75 1.89 -10.19 0 0 38 119 209 17,343 
Family Size** 20.55 14.99 21.43 11.87 -6.64 1 1 140 246 209 17,343 
Number of inventors 2.89 3.33 2.21 2.36 2.67 1 1 19 24 208 14,077 
Number of IPC Subclasses 2.59 1.05 1.71 0.24 -72.98 1 1 9 3 209 17,343 
   Patents assigned to litigating parties 
Backward citations 3.49 0.74 3.99 1.94 -17.92 0 0 21 23 209 2,941 
Forward citations 10.06 2.27 21.69 13.78 -7.53 0 0 161 524 209 2,941 
Non-patent references 1.83 0.51 3.75 2.92 -6.14 0 0 38 119 209 2,941 
Family Size** 20.55 17.93 21.43 15.43 -2.30 1 1 140 204 209 2,941 
Number of inventors 2.89 3.53 2.21 2.51 3.54 1 1 19 22 208 2,467 
Number of IPC Subclasses 2.59 1.06 1.71 0.26 -41.98 1 1 9 3 209 2,941 
Non-litigated control patents matched to litigated patents on priority filing year and authority as well as IPC subsclasses. 
  * All differences are statistically significant at <5% level. 
        ** Defined according to EPO'S DOCDB family definition. 
         
            
Table 9: PHC -- Outcome and duration, 2000-2008 
Final Judgement # Cases % Duration* 
  Reason     Mean Median 
Yes 
 
125 49.02 2.92 3 
No 
 
126 49.41 2.09 2 
 
settled 70 55.56 
  
 
other 22 17.46 
  
 
na 34 26.98 
  NA   4 1.57 na na 
* In years; computed as difference between year in which claim form was 
issued and final judgment or end of court case (if known) 
 
              
Table 10: PHC -- Judgment and characteristics of patent cases, 2000-2008 
 
Claimant Defendant 
Number 
of parties 
Final Judgment Final Judgment 
Yes No NA Yes No NA 
1 46.0% 52.0% 2.0% 40.9% 56.7% 2.3% 
2 55.0% 45.0% 0.0% 66.7% 33.3% 0.0% 
3 90.9% 9.1% 0.0% 64.3% 35.7% 0.0% 
4 33.3% 66.7% 0.0% 55.6% 44.4% 0.0% 
5 0.0% 100.0% 0.0% 33.3% 66.7% 0.0% 
6 0.0% 0.0% 0.0% 100.0% 0.0% 0.0% 
>6 0.0% 0.0% 0.0% 100.0% 0.0% 0.0% 
Sum 49.0% 49.4% 1.6% 49.0% 49.4% 1.6% 
        
                
Table 11: PHC -- Claim and judgment of patent cases, 2000-2008 
Claim All Outcome 
    Infringed 
Valid, not 
infringed Revoked* Settled Other NA 
Infringement 109 14.7% 10.1% 25.7% 23.9% 11.9% 13.8% 
Revocation 79 3.8% 19.0% 41.8% 25.3% 7.6% 2.5% 
Other 29 6.9% 3.4% 3.4% 13.8% 58.6% 13.8% 
NA 38 0.0% 0.0% 0.0% 52.6% 2.6% 44.7% 
* Includes partial revocation 
       
